Clinical Rheumatology

, Volume 26, Issue 10, pp 1693–1700

Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience

  • Liisa Konttinen
  • Riitta Tuompo
  • Tea Uusitalo
  • Riitta Luosujärvi
  • Kari Laiho
  • Jukka Lähteenmäki
  • Maija Puurtinen-Vilkki
  • Ritva Lanteri
  • Saara Kortelainen
  • Helena Karilainen
  • Tuire Varjolahti-Lehtinen
  • Dan Nordström
Original Article

DOI: 10.1007/s10067-007-0574-5

Cite this article as:
Konttinen, L., Tuompo, R., Uusitalo, T. et al. Clin Rheumatol (2007) 26: 1693. doi:10.1007/s10067-007-0574-5

Abstract

Biological therapy for ankylosing spondylitis (AS) has led to improved disease control beyond that of conventional treatments. International recommendations encourage clinicians prescribing biological treatments to register patients in national registers to collect information on outcome and toxicity. Patients with AS (n = 229) from the Register of Biological Treatment in Finland (ROB-FIN) with severe disease of long duration were followed-up for up to 24 months. Due to an active disease, one or more concomitant disease-modifying antirheumatic drugs (DMARDs) were used by 86% at commencement of biological therapy. This add-on strategy with infliximab led to a rapid pain relief and improvement of patient’s and physician’s global assessments, C-reactive protein/erythrocyte sedimentation rate, and swollen and tender joint counts within 6 weeks. Concomitant use of NSAID and oral corticosteroid was reduced. Corresponding results were documented at 3 months with etanercept, which was more recently approved for the treatment of spondyloarthropathies. Seventy-nine percent of the patients were ASAS 20 responders. A subgroup of AS patients with only axial involvement (n = 46) responded correspondingly. The first biological drug was discontinued in only 7% due to lack of efficacy and in 6% due to adverse events. Anti-TNF agents, often used in combination with DMARDs, appeared to have persistent effectiveness and limited toxicity in a real-life clinical setting in a cohort of Finnish AS patients with severe disease and long disease duration.

Keywords

Ankylosing spondylitisBiologicalsCombination therapy

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  • Liisa Konttinen
    • 1
  • Riitta Tuompo
    • 2
  • Tea Uusitalo
    • 2
  • Riitta Luosujärvi
    • 2
    • 3
  • Kari Laiho
    • 4
    • 10
  • Jukka Lähteenmäki
    • 5
  • Maija Puurtinen-Vilkki
    • 6
  • Ritva Lanteri
    • 7
  • Saara Kortelainen
    • 3
  • Helena Karilainen
    • 8
  • Tuire Varjolahti-Lehtinen
    • 9
  • Dan Nordström
    • 1
    • 2
  1. 1.University of HelsinkiHelsinkiFinland
  2. 2.Division of Medicine and RheumatologyHelsinki University Central HospitalHelsinkiFinland
  3. 3.Kuopio University HospitalKuopioFinland
  4. 4.Rheumatism Foundation HospitalHeinolaFinland
  5. 5.Joensuu Central HospitalJoensuuFinland
  6. 6.Turku University Central HospitalTurkuFinland
  7. 7.Seinäjoki Central HospitalSeinäjokiFinland
  8. 8.Rauma HospitalRaumaFinland
  9. 9.Tampere University HospitalTampereFinland
  10. 10.Department of Musculoskeletal Medicine, Medical SchoolUniversity of TampereTampereFinland